Brand Name: Myrbetriq
Generic Name: mirabegron
Medication Class: Beta-3 adrenergic agonist
Similar Drugs: None
Manufacturer: Astellas Pharma Technologies, Inc.
FDA Approval Date: June 2012
What is Myrbetriq and its mechanism of action?
Myrbetriq is a prescription only medication that reduces symptoms of overactive bladder (OAB) such as urinary urgency, urinary frequency, nocturia, or urge incontinence. As we age, the likelihood of developing overactive bladder increases. Myrbetriq works by stimulating beta-3 adrenergic receptors within the body. Stimulating beta-3 adrenergic receptors relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle, increasing the bladder’s storage capacity.
What is Myrbetriq used for?
Myrbetriq is used for the treatment of overactive bladder (OAB) with symptoms of urinary frequency, urgency, or urge incontinence. About 46 million male and female Americans 40 years of age or older experience OAB symptoms. OAB can sometimes lead to accidental wetting.
How effective is Myrbetriq?
In a clinical study, 1994 patients were studied for 12 weeks. Each patient had OAB diagnosed within the last 3 months, at least 8 micturitions per day, and experienced urgency with or without incontinence in the past 3 days. Patients received placebo, Myrbetriq 25 mg, or Myrbetriq 50 mg. The primary endpoints were a change from baseline in the number of incontinence episodes per day and a change in the number of micturitions per day. Myrbetriq 25 mg was effective in treating OAB within 8 weeks and Myrbetriq 50 mg was effective in treating OAB within 4 weeks. Use of Myrbetriq reduced the number of incontinence episodes and number of micturitions per day better than placebo. The change in the number of micturitions per day was -1.18 for placebo, -1.65 for Myrbetriq 25 mg, and -1.60 for Myrbetriq 50 mg.
Interesting fact about Myrbetriq.
Myrbetriq is effective within 4 to 8 weeks.
Myrbetriq maximum blood concentrations are higher in females than males.